155 related articles for article (PubMed ID: 26692910)
1. Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors.
Geybels MS; Alumkal JJ; Luedeke M; Rinckleb A; Zhao S; Shui IM; Bibikova M; Klotzle B; van den Brandt PA; Ostrander EA; Fan JB; Feng Z; Maier C; Stanford JL
Clin Epigenetics; 2015; 7():128. PubMed ID: 26692910
[TBL] [Abstract][Full Text] [Related]
2. Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue.
Geybels MS; Zhao S; Wong CJ; Bibikova M; Klotzle B; Wu M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Prostate; 2015 Dec; 75(16):1941-50. PubMed ID: 26383847
[TBL] [Abstract][Full Text] [Related]
3. Calcium Channel Blocker Use and Risk of Prostate Cancer by TMPRSS2:ERG Gene Fusion Status.
Geybels MS; McCloskey KD; Mills IG; Stanford JL
Prostate; 2017 Feb; 77(3):282-290. PubMed ID: 27753122
[TBL] [Abstract][Full Text] [Related]
4. Aspirin and NSAID use in association with molecular subtypes of prostate cancer defined by TMPRSS2:ERG fusion status.
Wright JL; Chéry L; Holt S; Lin DW; Luedeke M; Rinckleb AE; Maier C; Stanford JL
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):53-6. PubMed ID: 26503111
[TBL] [Abstract][Full Text] [Related]
5. Insulin-like growth factor 1 receptor affects the survival of primary prostate cancer patients depending on TMPRSS2-ERG status.
Mancarella C; Casanova-Salas I; Calatrava A; García-Flores M; Garofalo C; Grilli A; Rubio-Briones J; Scotlandi K; López-Guerrero JA
BMC Cancer; 2017 May; 17(1):367. PubMed ID: 28545426
[TBL] [Abstract][Full Text] [Related]
6. Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
Gerke JS; Orth MF; Tolkach Y; Romero-Pérez L; Wehweck FS; Stein S; Musa J; Knott MML; Hölting TLB; Li J; Sannino G; Marchetto A; Ohmura S; Cidre-Aranaz F; Müller-Nurasyid M; Strauch K; Stief C; Kristiansen G; Kirchner T; Buchner A; Grünewald TGP
Int J Cancer; 2020 Apr; 146(7):2036-2046. PubMed ID: 31732966
[TBL] [Abstract][Full Text] [Related]
7. Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
Egbers L; Luedeke M; Rinckleb A; Kolb S; Wright JL; Maier C; Neuhouser ML; Stanford JL
Am J Epidemiol; 2015 May; 181(9):706-13. PubMed ID: 25852077
[TBL] [Abstract][Full Text] [Related]
8.
Bauer S; Ratz L; Heckmann-Nötzel D; Kaczorowski A; Hohenfellner M; Kristiansen G; Duensing S; Altevogt P; Klauck SM; Sültmann H
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33669024
[TBL] [Abstract][Full Text] [Related]
9. ERG deregulation induces IGF-1R expression in prostate cancer cells and affects sensitivity to anti-IGF-1R agents.
Mancarella C; Casanova-Salas I; Calatrava A; Ventura S; Garofalo C; Rubio-Briones J; Magistroni V; Manara MC; López-Guerrero JA; Scotlandi K
Oncotarget; 2015 Jun; 6(18):16611-22. PubMed ID: 25906745
[TBL] [Abstract][Full Text] [Related]
10. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
11. T2E (TMPRSS2-ERG) fusion transcripts are associated with higher levels of AMACR mRNA and a subsequent prostate cancer diagnosis in patients with atypical small acinar proliferation.
Eryilmaz IE; Kordan Y; Vuruskan BA; Kaygısız O; Tunca B; Cecener G
Gene; 2018 Mar; 645():69-75. PubMed ID: 29277318
[TBL] [Abstract][Full Text] [Related]
12. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
[TBL] [Abstract][Full Text] [Related]
13. Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature.
Li Y; Su H; Liu K; Zhao Z; Wang Y; Chen B; Xia J; Yuan H; Huang DS; Gu Y
World J Surg Oncol; 2024 Feb; 22(1):49. PubMed ID: 38331878
[TBL] [Abstract][Full Text] [Related]
14. A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers.
Gasi Tandefelt D; Boormans JL; van der Korput HA; Jenster GW; Trapman J
Eur Urol; 2013 Dec; 64(6):941-50. PubMed ID: 23490727
[TBL] [Abstract][Full Text] [Related]
15.
Geybels MS; Fang M; Wright JL; Qu X; Bibikova M; Klotzle B; Fan JB; Feng Z; Ostrander EA; Nelson PS; Stanford JL
Oncotarget; 2017 Oct; 8(48):84338-84348. PubMed ID: 29137428
[TBL] [Abstract][Full Text] [Related]
16. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1.
Liu B; Gu X; Huang T; Luan Y; Ding X
Oncol Rep; 2017 Jan; 37(1):201-208. PubMed ID: 28004109
[TBL] [Abstract][Full Text] [Related]
17. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation.
Börno ST; Fischer A; Kerick M; Fälth M; Laible M; Brase JC; Kuner R; Dahl A; Grimm C; Sayanjali B; Isau M; Röhr C; Wunderlich A; Timmermann B; Claus R; Plass C; Graefen M; Simon R; Demichelis F; Rubin MA; Sauter G; Schlomm T; Sültmann H; Lehrach H; Schweiger MR
Cancer Discov; 2012 Nov; 2(11):1024-35. PubMed ID: 22930729
[TBL] [Abstract][Full Text] [Related]
19. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
[TBL] [Abstract][Full Text] [Related]
20. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.
Tian TV; Tomavo N; Huot L; Flourens A; Bonnelye E; Flajollet S; Hot D; Leroy X; de Launoit Y; Duterque-Coquillaud M
Oncogene; 2014 Apr; 33(17):2204-14. PubMed ID: 23708657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]